The company has not filed an annual or quarterly report since its FY2024 10-K, filed Mar 26, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Feb 11, 2026.
10-K for FY2024, filed Mar 26, 2025
The sections below describe the company as of the FY2024 annual report.
Sells GentleWave root-canal treatment systems and single-use procedure instruments to endodontists and general dentists.
10-K for FY2024, filed Mar 26, 2025
Dental practitioners buy consoles, procedure instruments and accessories, with payment typically on open credit terms. Product sales are tied to when the goods transfer to customers; service contracts and technical support earn revenue over the service period.
10-K for FY2024, filed Mar 26, 2025Product revenue is generated from sales of the GentleWave Console and related PIs and accessories. The Company’s products are sold…View ↗
The Company’s performance obligations primarily arise from the manufacture and delivery of the GentleWave System, related PIs and…View ↗
Product revenue is recognized at a point in time when the Company has transferred control to the customer, which is generally when title of…View ↗
Revenue for technical support and other services is recognized ratably over the performance obligation period.View ↗
$33.2M
10-K for FY2024, filed Mar 26, 2025
$33.2M ↗
Endodontists and general dentists who perform many root canals buy the GentleWave System directly from the company's field sales force in the United States and Canada.
10-K for FY2024, filed Mar 26, 2025
No. It lost $28M in FY2024.
10-K for FY2024, filed Mar 26, 2025
−$29.4MView ↗
10-K for FY2024, filed Mar 26, 2025
−$28MView ↗
10-K for FY2024, filed Mar 26, 2025
−$24.9MView ↗
Grew. Revenue grew 42% in 4 years, from $23.4M in FY2020 to $33.2M in FY2024, about 9% a year.
Competes with Dentsply Sirona, Envista, and Henry Schein
10-K for FY2024, filed Mar 26, 2025Our proprietary technology platform represents an innovative approach to the treatment of tooth decay. As a result, our treatment method…View ↗
Loading...